Reading a Longevity Study: Mice Aren't Men

“Extends lifespan” is a claim about a specific animal, in a specific colony, on a specific diet — and the species is the first thing dropped when the finding travels. The useful question is not whether mouse work matters (it does), but how much a mouse lifespan number should move your beliefs about a human one. There is a good way to answer that, because one program has spent two decades doing mouse lifespan studies properly, and separate work has quantified how often animal results survive the trip to people.

The gold standard: three sites, one protocol, all results published

The National Institute on Aging’s Interventions Testing Program (ITP) was set up to remove the usual escape hatches. Every compound is tested in parallel at three sites — The Jackson Laboratory, the University of Michigan, and the University of Texas Health Science Center — in genetically heterogeneous mice bred from a four-way cross, so no result depends on one lab’s water, chow, or inbred strain. And, as the program states in its own reports, “it is the goal of the ITP to publish all results, negative or positive.”

That design produces a short list of survivors. Rapamycin is the clearest. In the 2009 Nature report, mice given rapamycin in food starting at 600 days of age — already late life — showed median lifespan increases of 9% in males and 13% in females. A later ITP cohort dosed from 9 months of age extended median survival by an average of 10% in males and 18% in females, with significant increases in lifespan, including maximum lifespan, at each of the three test sites. Replication across independent sites is the part that matters; a single-lab result of the same size would carry far less weight.

The list of compounds that did not survive is longer, and more familiar.

Compound (ITP, genetically heterogeneous mice)	Lifespan result
Rapamycin	Median survival +10% males, +18% females; significant at all three sites
Resveratrol (300 and 1200 ppm)	No significant effect in either sex
Simvastatin (12 and 120 ppm)	No significant effect in either sex
Green tea extract	No significant effect by log-rank test
Curcumin	No significant effect by log-rank test
Oxaloacetic acid	No significant effect by log-rank test
Medium-chain triglyceride oil	No significant effect by log-rank test

Resveratrol, curcumin and green tea extract are among the most heavily marketed longevity compounds on the internet. Tested against the ITP’s replicated protocol, none of them extended the lifespan of male or female mice.

Then there is the species gap on top

Suppose a compound clears that bar. A 2024 umbrella review in PLoS Biology pooled 122 systematic and scoping reviews covering 54 human diseases and 367 therapeutic interventions tested in animals. Among therapies with at least ten years of development time, 50% entered any human study, 40% reached a randomized controlled trial, and 5% obtained regulatory approval. Median transition times were 5 years to a first human study, 7 years to an RCT, and 10 years to approval.

The same analysis found 86% concordance between positive animal results and positive clinical results (relative risk 0.86, 95% CI 0.80 to 0.92) — meaning the drop-off is less about animals lying and more about how many candidates fall out at every later stage, for reasons of dose, safety, effect size and trial design. Either way, the arithmetic for a reader is the same: a positive mouse result is early, and most early things do not arrive.

What to check when you read a longevity claim

• What species, and was it replicated? One lab, one strain, one cohort is a hypothesis. Three sites on one protocol is evidence.
• Was the negative result publishable? Programs that only report hits generate a literature made of hits.
• Median or maximum lifespan? They answer different questions, and the harder one to move is maximum.
• Which sex? Several ITP results differ substantially between males and females, rapamycin included.
• Is there any human data at all? For most longevity compounds the honest answer is no controlled human lifespan trial exists, and none is running.

The takeaway

A replicated mouse lifespan result is genuinely meaningful — it is the strongest preclinical signal this field produces, and it is how rapamycin earned its position. It is still not a human result. Only about 5% of animal-tested interventions reach approval, and the median route takes a decade. Where a compound has failed the ITP outright, as resveratrol, curcumin and green tea extract did, the reasonable conclusion is not “unproven in humans” but “tested carefully in mice and found to do nothing.” For more on how that gap plays out compound by compound, see animal data vs human data and why most longevity supplements disappoint.

Sources

• Rapamycin fed late in life extends lifespan in genetically heterogeneous mice (Nature, 2009, via PMC)
• Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice (J Gerontol A Biol Sci Med Sci, 2011, via PMC)
• Evaluation of resveratrol, green tea extract, curcumin, oxaloacetic acid, and medium-chain triglyceride oil on life span of genetically heterogeneous mice (J Gerontol A Biol Sci Med Sci, 2013)
• Analysis of animal-to-human translation shows that only 5% of animal-tested therapeutic interventions obtain regulatory approval for human applications (PLoS Biology, 2024, via PMC)

This is sample content created during site scaffolding. Sources have been attached but each claim still needs verification against them before launch.